Pembrolizumab and Stage II Melanoma: KEYNOTE-716 Trial Results Will Open Path to a New Treatment Paradigm for High‑Risk Tumors
Pembrolizumab significantly reduces the risk of recurrence compared with placebo in patients with high‑risk stage IIB/C melanoma after complete resection.
KEYNOTE-716 was a global, double‑blind, Phase III randomized, placebo‑controlled trial that evaluated adjuvant pembrolizumab (200 mg every 3 weeks) versus placebo in patients with high‑risk stage IIB/C melanoma after complete resection. The study randomized ~1,000 patients across 150 centers and demonstrated a significant improvement in recurrence‑free survival (HR 0.61; 95% CI 0.45‑0.82) and a lower overall recurrence rate (11.1% vs 16.8% at 12 months). Adverse events were manageable, with Grade III/IV events in 16.1% of the pembrolizumab group.
These findings establish pembrolizumab as an effective adjuvant therapy for high‑risk stage II melanoma, shifting the treatment paradigm from surgery alone to combined immunotherapy, potentially reducing recurrence and improving long‑term outcomes and influencing clinical guidelines.
Bizonyítékszint: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Kapcsolódó jelek
- Beyond the Five-Year Milestone: Long‑term Survivorship of Melanoma Patients Treated Off‑Trial with anti‑PD‑1
- Uveal Melanoma – Trials in Disease – Overview of Information and Clinical Research
- A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma
- Melanoma Research
- The Clinical Trial Landscape for Melanoma Therapies